CRISPR Therapeutics AG CRSP
Our mission is to create transformative gene-based medicines for serious human diseases. 10-K, Item 1
- Headquarters
- Zug
- CEO
- Samarth Kulkarni
- Next results
- around Feb 11, 2027
What changed
26 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 12, 2026 against Feb 11, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
10 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 9 checks found nothing to note
-
Critical audit matters changedNew this year: Collaboration Expense, Net, Related to the Vertex Hemoglobinopathy Agreements (“As discussed in Note 8 to the consolidated financial statements, the Company accounts for elements of its Vertex Hemoglobinopathy Agreements with Vertex Pharmaceuticals, Inc. (or “Vertex”) under ASC 808. The Company records its share of the net profits and net losses, as applicable, for elements of ”). No longer listed: Estimation of Variable Consideration for ongoing Collaboration Agreements
-
Receivables -100.0% ($25.0M to $0) vs revenue -90.6% ($37.3M to $3.5M), -9.4 pts apart
8 more checks with nothing to note
-
Cash from operations −$345.0M vs net income −$581.6M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
26 paragraphs in Risk Factors that were not in the 10-K filed Feb 11, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
Vertex, generates product sales from CASGEVY, of which we receive 40% through our collaboration arrangement with Vertex. This amount is currently insufficient to cover program expenses and as such, we are responsible for 40% of losses, subject to certain limitations. We currently generate no revenue from sales of any wholly-owned…
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
Similarly, relatively few siRNA product candidates have been tested in humans and to date few have received regulatory approval and market authorizations.
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
Any government investigation of alleged violations of law, including investigations of any of our vendors, could require us to
-
Item 1A · new paragraph · not in the 10-K filed Feb 11, 2025 10-K, ITEM 1A
CASGEVY For SCD Has Received A Commissioner’s National Priority Voucher. The Benefits Of Such A Voucher, Including A Potentially Accelerated Timeline For Review Of Any [sBLA] Submission For CASGEVY For SCD By The FDA, May Not Be Able To Be Fully Realized. In June 2025, the FDA announced the creation of a new program, the Commissioner’s…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.2M | $371.2M | $37.3M | $3.5M |
| Net income | −$650.2M | −$153.6M | −$366.3M | −$581.6M |
| Operating cash flow | −$495.7M | −$260.4M | −$142.8M | −$345.0M |
| Free cash flow | −$532.9M | −$269.8M | −$144.7M | −$345.9M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$3.5M ▼ 90.6% in FY2025−$581.6M in FY2025−$345.9M in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 6, 2026RAJU PRASAD (Officer) gave notice of a planned sale of 79,393 shares worth about $4.0M Form 144, approximate sale date Nov 6, 2026
-
8-KNov 2, 2026Quarterly results 8-K item 2.02
-
10-QNov 2, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
OfficerOct 19, 2026CFO change Silver’s appointment to the position of Chief Financial Officer, the Company’s wholly owned subsidiary, CRISPR Therapeutics, Inc (“CRISPR Inc.”), entered into an Employment Agreement with Mr.
About the company
CRISPR Therapeutics AG, Zug · from the 10-K filed Feb 12, 2026
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.
- Headquarters
- Zug
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 2, 2026
- Incorporated in
- Switzerland
Email alerts
Sources
The 10-K filed Feb 12, 2026 (open at SEC), compared with the 10-K filed Feb 11, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CRSP/export.csv") into a cell.